The FDA rejected Summit Therapeutics and Akeso’s ivonescimab in a narrow non-small cell lung cancer setting, citing a lack of overall survival benefit despite evidence the therapy slowed disease progression. In a letter to the companies, regulators said the absence of a survival-improving effect meant the treatment could not demonstrate a favorable benefit-risk profile for approval. The decision follows the program’s earlier clinical signal on tumor control, but underscores how survival endpoints remain decisive for checkpoint-based combinations. For investors and trial designers, the ruling highlights the continued regulatory bar for dual-mechanism oncology antibodies—particularly combinations spanning immune checkpoint and angiogenesis pathways—where response and progression metrics alone have not been sufficient.